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Abstract
Background: The effectiveness of neoadjuvant treatment (NT) prior to resection of squamous
cell carcinoma of the esophagus (SCCE) in terms of prolonged survival has not been proven by
randomized trials. Facing considerable financial expenses and with concerns regarding the
consumption of the patient's remaining survival time, this study aims to provide rationales for
pretreating resection candidates.
Methods: From March 1986 to March 1999, patients undergoing resection for SCCE were
documented prospectively. Since 1989, NT was offered to patients with mainly upper and middle
third T3 or T4 tumors or T2 N1 stage who were fit for esophagectomy. Until 1993, NT consisted
of chemotherapy. Since that time chemoradiation has also been applied. The parameters for
expense and benefit of NT are costs, pretreatment time required, postoperative morbidity and
mortality, clinical and histopathological response, and actuarial survival.
Results: Two hundred and three patients were treated, 170 by surgery alone and 33 by NT +
surgery. Postoperative morbidity and mortality were 52% to 30% and 12% to 6%, respectively (p =
n.s.). The response to NT was detected in 23 patients (70%). In 11 instances (33%), the primary
tumor lesion was histopathologically eradicated. Survival following NT + surgery was significantly
prolonged in node-positive patients with a median survival of 12 months to 19 months (p = 0.0193).
The average pretreatment time was 113 ± 43 days, and reimbursement for NT to the hospital
amounted to Euro 9.834.
Conclusions:  NT did not increase morbidity and mortality. Expenses for pretreatment,
particularly time and costs, are considerable. However, taking into account that the results are
derived from a non-randomized study, patients with regionally advanced tumor stages seem to
benefit, as seen by their prolonged survival.
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Background
Neoadjuvant treatment (NT) of esophageal squamous
cell cancer (SCCE) prior to surgery was thought to im-
prove survival by reduction of the primary tumor lesion
as well as of regional and systemic tumor spread [1,2].
Meanwhile, to many gastroenterologists and surgeons,
cytotoxic therapy prior to surgery appears to be a stand-
ard concept. However, until now, prospective rand-
omized trials could not prove the effectiveness of chemo-
or chemoradiotherapy in terms of prolonged survival or
a higher rate of cure, particularly in squamous cell carci-
noma [3–6]. Additionally, there is an ongoing discussion
on substantial risks of pretreatment to increase postop-
erative morbidity and mortality [7,8]. Furthermore, con-
siderable expenses in time and money have to be
accepted when expecting neoadjuvant protocols to be
beneficial. Facing considerable uncertainty upon effec-
tiveness of NT we undertook a one-institution analysis to
investigate whether application of NT nowadays is justi-
fied in terms of expenses and survival benefit.
Methods
From May 1986 to March 1999, all patients carrying
SCCE who were referred to our surgical department were
documented prospectively. The patients underwent ei-
ther transthoracic or transhiatal subtotal esophagecto-
my. Reconstruction of the intestinal route was achieved
mostly using a gastric tube and in cases with previous
gastric resection using colonic esophago-gastric interpo-
sition. Since 1989, NT was offered to patients with tu-
mors mainly of the upper and middle third who all were
staged by means of a computed tomography (CT) scan
and endoscopic ultrasonography either T3/4 NX, or T2
N1, according to the 1992 UICC classification [9]. Indi-
viduals obviously not suitable for esophagectomy were
denied surgery and underwent endoscopic palliation.
The majority of pretreatments were performed at our
university hospital by the Departments of Gastroenterol-
ogy (n = 20) and Hematology (n = 5), some in outside
hospitals (n = 8).
The neoadjuvant regimen during an initial period until
1993 consisted of chemotherapy with two cycles of cispl-
atin (100 mg/m2) on day 1 along with 5-fluorouracil (400
mg/m2 per day) on days 1 to 5. Participating in a multi-
center trial comparing the effect of chemoradiotherapy +
surgery to chemoradiation alone, we switched to three
cycles of 5-fluorouracil, leucovorin, etoposid, and cispla-
tin, followed by an initial dose of etoposid and cisplatin,
and radiation of 40 Gy with 5 ×  2 Gy for 4 weeks [10], so
called FLEP + radiation (Fig. 1). This resulted in 19 pa-
tients recieving chemotherapy alone, 14 cases underwent
chemo- and radiotherapy. Esophagectomy was per-
formed in all instances within 2–4 weeks after the end of
pretreatment.
Of particular interest was the length of the time period
from histological confirmation of the diagnosis of es-
ophageal malignancy to the day of surgery after NT. Ad-
ditionally, the costs for the currently applied NT protocol
FLEP + radiation were calculated. The response to pre-
treatment was classified clinically according to improve-
ment of the ability to swallow and/or radiologically as, at
least, a 50% reduction of the primary tumor size as "re-
sponse", "no change", or "progression". Surgical morbid-
ity was defined as "none", "minor" (e.g., insufficiency of
the cervical anastomosis without systemic inflammatory
response), or "major" (e.g., prolonged mechanical venti-
lation more than 7 days and any kind of abdominal or
thoracic reoperation). Data on survival status were ob-
tained by requests directed to the respective county ad-
ministration.
Results are expressed as means and standard deviation
or percentages. To test for significant differences, the
student's t-test (two-tailed) was applied for continuous
data and Fisher's exact test was applied for categories.
Overall survival including in-hospital deaths was esti-
mated according to the Kaplan-Meier method [11] and
comparison of significant differences in survival was cal-
culated using the log-rank test. A p-value of < 0.05 was
considered statistically significant.
Results
Resection was performed in 203 patients; of these, 33
underwent pretreatment with the intention of perform-
ing subsequent resection. A comparison of both groups
with regard to surgical procedures and patient character-
istics is given in Table 1. Pretreated patients were, on av-
erage, somewhat younger and had a significantly shorter
observation period. To compare tumor stages, the situa-
tion before NT was considered appropriate in the com-
Figure 1
Schedule of cytotoxic interventions within the FLEP + radia-
tion protocol. Medication is given for each cycle.BMC Cancer 2001, 1:20 http://www.biomedcentral.com/1471-2407/1/20
bined treatment group. Because precise and prospective
staging prior to resection was not sufficiently available in
the surgery alone group, because it was not the prerequi-
site to decide on pretreatment or not, the final his-
topathological result was the source of TNM staging in
those patients (Table 2).
According to our inclusion criteria, there were signifi-
cantly more T3 and T4 tumors and also a higher percent-
age of node positive patients in the combined modality
group than in the group undergoing surgery alone. In
contrast, the latter included considerably more early T1
and T2 stages.
To the best of our knowledge, cytotoxic pretreatment,
performed with no special prospective documentation in
internal medicine departments, caused neither major
morbidity nor mortality. With regard to the response to
NT, there was relief of esophageal obstruction and or re-
duction of tumor size in 23 of 33 cases (70%), no change
detected in 7 (21%), and progression in 3 (9%) patients.
There was no difference in the response rate between pr-
eoperative chemotherapy with 13 of 19 (68%) and chem-
oradiotherapy with 10 of 14 (71%). Viable cells of the
primary tumor lesion were no longer found in 11 of 33
(33%) resected specimens of patients after cytotoxic pre-
treatment, but two had either nodal or distant tumor
spread. The percentage of potentially curatively resected
cases was 70% in the surgery-alone group and 82% in the
NT modality (p = n.s.). Hospital mortality following re-
section was 2 out of 33 (6%) in the NT group. It consisted
of two septic multiorgan failures (MOF) post anastomot-
ic leakage and postoperative pancreatitis, respectively.
This was not elevated relative to surgery alone with 21
out of 170 (12%) (p = n.s.). Causes of death among pa-
tients with surgery alone were pneumonia and consecu-
tive MOF (n = 8), anastomotic leakage (n = 4), pleura
empyema (n = 3), bleeding and MOF (n = 2), hepatic fail-
ure (n = 2), and isolated heart disease (n = 2). Mortality
numbers corresponded to fewer cases of postoperative
morbidity after NT with 30% to 54% (p = 0.0215) and
fewer days of postoperative hospital stay [23.4 ± 16.8 vs
30.1 ± 19.7 days (p = n.s.)].
Comparison of survival of all patients categorized in sur-
gery alone and NT + surgery revealed a slight but not sig-
nificantly better outcome after pretreatment (Fig. 2).
Two-year and five-year survival rates were 33% to 41%
and 17% to 26%, respectively. Calculating survival only
for T3- and T4-stages, the difference came close to but
did not reach the level of statistical significance (p =
0.0538). Significantly longer survival following NT +
Table 1: Baseline characteristics of 203 patients treated for squamous cell carcinoma of the esophagus.
Surgery alone (n = 170) NT + Surgery (n = 33) p-Value
Sex
- male 133 (78) 25 (76) 0.8102
- female 37 (22) 8 (24)
Age (years) 57.2 54.5 0.0714
Observation (years) 8.0 5.7 0.001
Tumor site
- upper / middle third 110 (65) 31 (94) 0.0004
- lower third 60 (35) 2 (6)
Type of resection
- transthoracic 112 (66) 26 (79) 0.16
- transhiatal 58 (34) 7 (21)
Type of reconstruction
- gastric tube 161 (95) 33 (100) 0.3601
- colonic interposition 9 (5) 0
Table 2: Tumor staging according to the UICC classification of 
1992.
Surgery alone NT + Surgery p-Value
(n = 170) (n = 33)
T1 30 (18) 0
T2 29 (17) 2 (6) 0.0007
T3 101 (59) 29 (88)
T4 10 (6) 2 (6)
N0 70 (41) 8 (24) 0.0795
N1 100 (59) 25 (76)BMC Cancer 2001, 1:20 http://www.biomedcentral.com/1471-2407/1/20
surgery was found when comparing all node-positive pa-
tients. Two-year and five-year survival rates were 23% to
43% and 10% to 28%, respectively (Fig. 3). Combining
T3/4 stages with N1 resulted in even more pronounced
prolongation of survival rates with 17% to 47% and 9% to
31% (p = 0.0096). Looking at the impact of the complete
histopathological response of the primary tumor lesion
on survival, we found a higher rate of survival at 2 years
following complete response (61% vs 31%) but an even
lower percentage at the 5-year margin (20% vs 31%).
Pretreatment for all 33 cases required an average of 113
± 43 days, counted from histologically confirmed diagno-
sis to surgery. Costs for NT were calculated for the most
recently applied protocol concept of FLEP + 40 Gy of ra-
diation. It consisted of 4 ×  7 days of hospital stay at the
Department of Gastroenterology (28 ×  Euro 233), 10
days at the Department of Radiation Oncology (10 ×
Euro 231), including Euro 7576 for cytotoxic drugs and
another Euro 1022 for outpatient radiation. This adds up
to Euro 9834, which will be the reimbursement for the
hospital only for NT. This also has to cover expenses for
the chemotherapy medication.
Discussion
The prognosis of SCCE, at least in locally advanced stag-
es, treated by surgery alone is disappointing. In particu-
lar, early local spread to adjacent structures and
lymphatics and the natural limits for surgical radicality
within the mediastinum render five-year survival rates in
unselected patient cohorts to a level of about 15% [12–
14]. This was and is the rationale behind the attempt, us-
ing cytotoxic pretreatment, to reduce both the primary
tumor size and the potentially regional and early single
cell systemic spread. The phenomenon of response, in
some instances disappearance of viable tumor cells his-
topathologically [15], has led to widespread application
of neoadjuvant regimens without having proved by
means of controlled randomized trials that this will im-
prove long-term survival [16,17].
One prerequisite to decide whether NT has the potential
to prolong survival is to focus on a single tumor entity.
Even recent randomized studies [6,18] have included ad-
eno- and squamous cell carcinoma. Since the latter is
known to be more susceptible to radiation, a potential
benefit for this subgroup might be missed. The basis of
comparing surgery alone with NT + surgery has to be the
tumor status prior to pretreatment. Walsh et al. did find
NT effective in adenocarcinoma of the esophagus but
they gave no detailed information regarding the tumor
stages prior to chemoradiation [19].
Response rates to neoadjuvant regimens range from 19%
in previous studies [6] to 70% in our setting. Complete
disappearance of viable tumor cells after cytotoxic pre-
treatment was observed in 2.5% [6] to 51% [20]. These
numbers probably reflect, to a certain degree, the quality
of treatment or at least its consequent application, which
might be a problem in large multicenter trials [6]. Now-
adays, response rates of more than 50% and pathologi-
cally complete eradication of the primary tumor in about
20% seem to be a standard to call pretreatment suffi-
ciently effective [4,15,21]. A certain hint that NT has its
limitations in case of tumor spread to the lymphatic sys-
tem or even distant organs is the fact that it caused 11 pri-
mary tumor lesions to be histopathologically eradicated
but left two with regional or distant metastases.
Figure 2
Comparison of survival of all patients undergoing surgery
alone and NT + surgery. Median survival time was 13.9 and
20.3 months, respectively.
Figure 3
Comparison of survival of all node positive patients undergo-
ing surgery alone and NT + surgery. Median survival time
was 12.0 and 19.1 months, respectively.BMC Cancer 2001, 1:20 http://www.biomedcentral.com/1471-2407/1/20
There is a continuing debate regarding whether cytotoxic
regimens prior to resection carry the risk of increasing
morbidity or mortality [7]. During the eighties, mortality
seemed to be negatively influenced by chemotherapy be-
fore surgery [8]. In recent years, there have been reports
of myelosuppression in those patients [22], but obvious-
ly this does not have a negative impact on the patient's fi-
nal clinical outcome [3,18,21]. Also, in our experience,
we found no significant difference between surgery alone
and NT + surgery with regard to morbidity and mortali-
ty. Lower numbers after NT + surgery most likely are an
expression of improved postoperative care in recent
years.
Looking at long-term survival of all patients (Fig. 2), pre-
treated patients did better despite the fact that this group
included more advanced tumor stages. However, this
difference did not reach statistical significance. Reduc-
ing analysis to locally advanced stages T3 and T4 result-
ed in a difference being close to significant. This was
clearly achieved by comparing only node-positive pa-
tients (Fig. 3) and was even more pronounced in those
with advanced tumor stages combined with positive
nodes. Despite small numbers and the non-randomized
setting of this study, this might be interpreted as evi-
dence that surgery alone was less able to control esopha-
geal cancer with regional or even single cell systemic
spread [23]. Facing the recurrence pattern of esophageal
carcinoma characterized by systemic organ metastases
in more than 30%, the effectiveness of wide local excision
with extensive lymph-node dissection is questioned
[24,25]. This might be one of the strongest arguments to
fight regional and systemic disease using cytotoxic pre-
treatment with final resection of the remaining disease.
Some randomized studies comparing surgery alone and
NT + surgery did not show significant differences in sur-
vival; these either included early stages, presumably
mostly without systemic disease [4], or did not exclude
them from entering the study [3,5,6], which might be one
reason for the failure in showing benefits of pretreat-
ment. A survival advantage in our study is primarily
shown for locally and regionally advanced stages.
An increasingly important issue is the phenomenon of
complete histopathological response of the primary tu-
mor lesion to chemo- or chemoradiotherapy. It is dis-
cussed as an independent positive prognostic factor.
Therefore, several authors call for means to identify re-
sponders before beginning the pretreatment [26,27],
thus excluding non-responders to avoid unnecessary
morbidity. To date, there are no means available to know
beforehand whether a patient will respond or not [28]. In
our study, we compared patients with T0-stages after NT
and resection with the other pretreated cases (Fig. 4). Al-
though there were higher survival rates at 2 years, both
curves merge at 5 years, which means prolongation of
median survival but not a higher chance of cure. Very
well aware of the fact that these are small numbers and
preliminary results, it might be hypothesized that the
complete responders are a biologically privileged sub-
group, identified by better reaction to cytotoxic pretreat-
ment, which could have a better outcome also without
NT.
In our study the average time period from histologically
proven diagnosis to resection was 113 ± 45 days in the NT
+ surgery group. This compared similarly to others [29]
with almost 20% of the median survival time of the re-
spective patient. Since this loss of time is combined with
treatment costs exclusively for the neoadjuvant modality
of around Euro 10,000, several authors question the use
of NT in resection of esophageal cancer [29].
Conclusion
Because we found considerable evidence in this non-ran-
domized historical case series that advanced tumor stag-
es seem to benefit from pretreatment, we would advocate
it for T3/4 and node-positive tumors in patients fit for re-
sective surgery. These findings have to be confirmed in
further well designed controlled randomized trials in-
cluding particularly T3/4-stages. Facing the economic
pressure to our health care system, it should only be ex-
ecuted in centers employing personnel well experienced
in this technique, with close cooperation of medical and
surgical faculties to minimize cytotoxic side effects, to re-
duce extra surgical morbidity, and to avoid pretreatment
of the wrong patients.
Figure 4
Comparison of survival of patients with complete histopatho-
logical eradication of the primary tumor lesion post NT (T0)
and those with residual viable tumor cells (T1-4). Median sur-
vival time was 27.8 and 13.6 months, respectively.BMC Cancer 2001, 1:20 http://www.biomedcentral.com/1471-2407/1/20
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